ClinicalTrials.gg
Active, not recruitingNCT05546099Updated Oct 23, 2026

Patient-driven Management of BP in CKD

An interventional study of Self-management of BP medications and Self-monitoring of home BP in Chronic Kidney Disease, sponsored by VA Office of Research and Development. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by VA Office of Research and Development · Not applicable, Interventional, and Treatment

How we know

Updated Oct 23, 2026Now Active, not recruitingStudy documents posted+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Renal Insufficiency, Chronic by VA Office of Research and Development — 5 open to participants now, 7 under way, none of them phase 3. Renal Insufficiency, Chronic · VA Office of Research and Development.

Enrollment
7th of 21
160 · median 100
Started
2022
the only one that year
No phase
10 of 22
3 open now
Registered
17th of 22
by date

Among the 22 studies in Renal Insufficiency, Chronic by VA Office of Research and Development, this one is the 7th largest by enrollment of the 21 interventional ones that give a count, is the only one that started in 2022, is one of 10 with no phase, and was the 17th registered.

Renal Insufficiency, Chronic

3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

5 of the 22 studies in Renal Insufficiency, Chronic by VA Office of Research and Development are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Renal Insufficiency, Chronic by VA Office of Research and Development, or all of them as a file.
02

Study summary

The proposed research will evaluate if patients managing their blood pressure medications under the guidance of a clinical pharmacist works better to lower blood pressure than patients monitoring their blood pressure at home and the standard care. 60 Veterans with chronic kidney disease (CKD) will be included in the study. The study will further evaluate factors that may influence the Veteran to accept the self-management approach and what factors in the VHA healthcare system affect the implementation of the self-management approach.

Read the detailed description

Chronic kidney disease (CKD) associates with high morbidity and mortality due to CKD progression and cardiovascular disease (CVD). Blood pressure (BP) lowering reduces the risk of CVD and CKD progression. In spite of the large number of BP medications available, a significant proportion of Veterans with CKD have BP above the goal. The current practice involves licensed providers performing medication titrations to achieve BP goals and is associated with limited patient engagement. The investigators preliminary data indicate that the implementation of pharmacist-guided patient-driven titration of BP medications is effective and feasible in CKD. In this model, Veterans self-manage their BP medications under the guidance of the clinical pharmacist based on a pre-determined medication titration plan.

The prevalence of CKD is extremely high among Veterans, with some studies reporting a prevalence of 47% (vs 11% in the general population). Here, the investigators propose a novel interdisciplinary care model that engages the Veterans as an active participant in their care with the goal of improving BP control to improve long term outcomes. The application addresses a key HSR\&D priority (management of complex chronic disease).

The proposed care model is one that has not been tested and includes the clinical pharmacist working with the provider and the Veterans so that Veterans with CKD can self-manage their hypertension. While self-management is exercised in CKD once patients are on dialysis (via home dialysis modalities), the self-management approach is not utilized in the earlier stages of CKD. Importantly, in the approach, the investigators will utilize a transdisciplinary approach to evaluate the implementation of pharmacist-guided self-management of BP medications and the investigators will apply constructs of an implementation science framework, Consolidated Framework for Implementation Research (CFIR), to understand Veteran and system factors that may either facilitate or impede the implementation and sustainment of the pharmacist-guided self-management approach.

Specific aim 1 will evaluate if pharmacist-guided self-management of BP medications is more effective than self-monitoring of home BP + the standard care amongst Veterans with CKD. Specific aim 2 will identify and understand Veteran factors that may influence the acceptability of and the adherence to the self-management approach whereas specific aim 3 will focus on understanding system factors that may facilitate or impede the implementation of the self-management approach.

One hundred and sixty Veterans with uncontrolled hypertension and either stage 2 CKD with albuminuria or stage 3 and 4 CKD will be randomized to either pharmacist-guided self-management or to self-monitoring + the standard practice for 12 months. Aim 1 will evaluate change in [standardized] office systolic BP at 12 months as the primary outcome. Aim 2 will utilize a mixed methods approach including semi-structured interviews to evaluate a sample of 20 Veterans in each of the study arms. The investigators will further design data abstraction tools to evaluate the adherence to the intervention. In aim 3, the investigators will utilize CFIR constructs to guide the investigators qualitative semi-structured interviews with key organizational stakeholders including PACT clinical pharmacists, PCPs, and CKD providers (20 key stakeholders).

The PI will implement the pharmacist-guided self-management approach with the Pharmacy and Ambulatory care services as operational partners. The implementation of this approach will improve the patient experience (Survey of Healthcare Experiences of Patients) and the quality of care (Clinical Performance Measurement Program and the Strategic Analytics for Improvement and Learning).

03

Conditions studied

  • Chronic Kidney Disease

Keywords

  • kidney disease
  • hypertension
  • Home blood pressure
  • self-management
04

Who can participate

The criteria were revised on the registry on Oct 7, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Chronic kidney disease stage 3 or 4 (estimated : 15-59 milliliters per minute /1.73 square meters) or
  • Stage 2 chronic kidney disease (estimated GFR 60-89 milliliters per minute/1.73 square meters) with urinary albumin/creatinine ratio (ACR 300 milligrams per gram if no diabetes mellitus and 30 milligrams per gram if with diabetes mellitus), and
  • Uncontrolled hypertension defined as the avg of 2 readings > 140 systolic

Exclusion criteria

Exclusion Criteria:

  • Severely uncontrolled hypertension defined as systolic blood pressure (BP)>180
  • Patients with resistant hypertension and taking 4 blood pressure medications
  • Orthostatic hypotension defined as reduced systolic blood pressure by 20 millimeters of mercury or diastolic blood pressure by 10 millimeters of mercury after 3 minutes of standing
  • Severe chronic kidney disease defined as estimated \< 20 milliliters per minute /1.73 square meters
  • \<1 year
  • Severe liver disease
  • Severe congestive heart failure
  • Severe cognitive decline due to dementia
  • Pregnant, breastfeeding, or unwilling to use adequate
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
160 participants (actual)

Study arms

  • Experimental
    Self-management

    Patients monitor their home BP and self manage their BP medications based on a predesigned titration protocol and under the guidance of the clinical pharmacist.

    Behavioral: Self-management of BP medications

  • Active comparator
    Self-monitoring

    Patients monitor their home BP and contact their provider if the BP is above the goal.

    Behavioral: Self-monitoring of home BP

Interventions

  • BehavioralSelf-management of BP medications

    Patients will be educated on how to manage their home BP based on a pre-determined protocol. They will then monitor home BP and adjust meds accordingly and under the guidance of the clinical pharmacist.

  • BehavioralSelf-monitoring of home BP

    Patients will be educated on how to monitor home BP and will be educated to contact their primary care provider/CKD provider if the BP is above the goal.

06

What researchers measure

Primary outcomes

  1. Change in standardized office blood pressure (BP)

    Detailed procedure for standardized office BP measurement: This will be obtained by a trained research coordinator in accordance with the ACC/AHA and KDIGO (Kidney Disease Improving Global Outcomes) guideline.

    Time frame: 12 months

Secondary outcomes

  1. Change in conventional office blood pressure (BP)

    BP measured during standard of care clinical visits will be included.

    Time frame: 12 months

  2. Home blood pressure (BP) readings

    The average of the last 10 BP readings at home will be utilized a secondary outcome

    Time frame: 12 months

  3. Change in standardized office diastolic blood pressure (BP)

    Measured same as the primary outcome

    Time frame: 12 months

07

Study locations

1 site
08

References and documents

Publications

  • Good M, Hoskins R, Lund BC, Ten Eyck P, Dixon B, Cohen J, Reisinger Schact H, Kennelty K, Jalal D. A clinical trial evaluating pharmacist-guided self-management of hypertension among veterans with CKD, rationale and study design. Contemp Clin Trials. 2025 Jul;154:107950. doi: 10.1016/j.cct.2025.107950. Epub 2025 May 11. PubMed 40360073 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Only de- identified research data will be shared with the public. This will only be done under a data use agreement with the requesting entity. A Limited Dataset (LDS) will be created and shared pursuant to a Data Use Agreement (DUA) appropriately limiting use of the dataset and prohibiting the recipient from identifying or re-identifying (or taking steps to identify or re-identify) any individual whose data are included in the dataset. If a journal requires that the investigators share the data publicly, then and only then, would the investigators share that data via their requested path. However, no identifiable data, will be shared under any circumstance.

Supporting information: Study protocol, Statistical analysis plan

Time frame: This will be available after the study has concluded, anticipated November 2026 sometime.

Access criteria: Only de-identified data will be shared via a LDS and only upon request and completion of DUA.

09

Timeline

4 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2022 (actual). Primary completion is estimated for Dec 2026, 48 months after the start.

Of 580 non-industry interventional studies with no phase under Renal Insufficiency, Chronic, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 45. This study's planned 48 months is above that.

Counting every sponsor, half of 620 studies reached it within 23 months; a quarter within 10 and three quarters within 45.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 2, 2026: primary completion Sep 2026 → Dec 2026 and completion Nov 2026 → Sep 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2022
First posted
Sep 19, 2022
StartActual
Dec 15, 2022
Primary completionEst.
Dec 15, 2026was Sep 2026
CompletionEst.
Sep 30, 2027was Nov 2026
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 2, 2026
Primary completion
Sep 30, 2026→Dec 15, 2026
Oct 2, 2026
Study completion
Nov 20, 2026→Sep 30, 2027
Oct 2, 2026
Eligibility
Criteria revised in 2 updates
What changed on Oct 2, 2026
Inclusion criteria
  • RemovedAge >= 18 years,
  • EditedChronic kidney disease (CKD) stage 3 or 4 ([estimated glomerular filtration rate (GFR): 15-59 milliliters per minute (mL/min)/1.73m273 square meters (m2)] or
  • EditedStage 2 CKD (estimated GFR 60-89 mL/min/1.73m2) with urinary albumin/creatinine ratio (ACR) 300 mg/g if no diabetes mellitus (DM) and 30 milligrams per gram (mg/g) if with DM), and
Exclusion criteria
  • EditedSeverely uncontrolled hypertension defined as systolic blood pressure (BP )>180,
  • EditedOrthostatic hypotension defined as reduced systolic BP by 20 millimeters of mercury (mmHg) or diastolic BP by 10 millimeters of mercury (mmHg) after 3 minutes of standing,
  • EditedSevere chronic kidney disease (CKD) defined as estimated GFR < 20 milliliters per minute (mL/min)/1.73m2,73 square meters (m2)
What changed on Oct 7, 2026
Inclusion criteria
  • EditedChronic kidney disease (CKD) stage 3 or 4 [(estimated glomerular filtration rate (GFR): 15-59 milliliters per minute (mL/min)/1.73 square meters (m2)] or
  • EditedStage 2 CKDchronic kidney disease (estimated GFR 60-89 mL/minmilliliters per minute/1.73m273 square meters) with urinary albumin/creatinine ratio (ACR) 300 mg/gmilligrams per gram if no diabetes mellitus (DM) and 30 milligrams per gram (mg/g) if with DMdiabetes mellitus), and
Exclusion criteria
  • EditedPatients with resistant hypertension and taking 4 BPblood pressure medications
  • EditedOrthostatic hypotension defined as reduced systolic BPblood pressure by 20 millimeters of mercury (mmHg) or diastolic BPblood pressure by 10 millimeters of mercury (mmHg) after 3 minutes of standing
  • EditedSevere chronic kidney disease (CKD) defined as estimated GFRglomerular filtration rate < 20 milliliters per minute (mL/min)/1.73 square meters (m2)
across 2 updates, Oct 2, 2026 – Oct 7, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedChange in standardized office blood pressure (BP)Time frame: 12 months
Oct 2, 2026
Documents
Oct 23, 2026
Secondary outcomes
3 edited
What changed in the outcomes
  • EditedChange in conventional office blood pressure (BP)Time frame: 12 months
  • EditedHome blood pressure (BP) readingsTime frame: 12 months
  • EditedChange in standardized office diastolic blood pressure (BP)Time frame: 12 months
Oct 2, 2026
Design
Phase 3→Not applicable
Oct 14, 2026
Show all 4 updates
  1. Oct 23, 2026
    Documents Informed consent form ↗ posted
  2. Oct 14, 2026
    Design Phase 3→Not applicable
  3. Oct 7, 2026
    Eligibility 2 inclusion criteria edited; 3 exclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • EditedChronic kidney disease (CKD) stage 3 or 4 [(estimated glomerular filtration rate (GFR): 15-59 milliliters per minute (mL/min)/1.73 square meters (m2)] or
    • EditedStage 2 CKDchronic kidney disease (estimated GFR 60-89 mL/minmilliliters per minute/1.73m273 square meters) with urinary albumin/creatinine ratio (ACR) 300 mg/gmilligrams per gram if no diabetes mellitus (DM) and 30 milligrams per gram (mg/g) if with DMdiabetes mellitus), and
    Exclusion criteria
    • EditedPatients with resistant hypertension and taking 4 BPblood pressure medications
    • EditedOrthostatic hypotension defined as reduced systolic BPblood pressure by 20 millimeters of mercury (mmHg) or diastolic BPblood pressure by 10 millimeters of mercury (mmHg) after 3 minutes of standing
    • EditedSevere chronic kidney disease (CKD) defined as estimated GFRglomerular filtration rate < 20 milliliters per minute (mL/min)/1.73 square meters (m2)
    + 2 other changes: verification date and design details
  4. Oct 2, 2026
    Recruiting→Active, not recruiting
    Primary completion Sep 30, 2026→Dec 15, 2026
    Study completion Nov 20, 2026→Sep 30, 2027
    Eligibility 2 inclusion criteria edited, 1 removed; 3 exclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • RemovedAge >= 18 years,
    • EditedChronic kidney disease (CKD) stage 3 or 4 ([estimated glomerular filtration rate (GFR): 15-59 milliliters per minute (mL/min)/1.73m273 square meters (m2)] or
    • EditedStage 2 CKD (estimated GFR 60-89 mL/min/1.73m2) with urinary albumin/creatinine ratio (ACR) 300 mg/g if no diabetes mellitus (DM) and 30 milligrams per gram (mg/g) if with DM), and
    Exclusion criteria
    • EditedSeverely uncontrolled hypertension defined as systolic blood pressure (BP )>180,
    • EditedOrthostatic hypotension defined as reduced systolic BP by 20 millimeters of mercury (mmHg) or diastolic BP by 10 millimeters of mercury (mmHg) after 3 minutes of standing,
    • EditedSevere chronic kidney disease (CKD) defined as estimated GFR < 20 milliliters per minute (mL/min)/1.73m2,73 square meters (m2)
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedChange in standardized office blood pressure (BP)Time frame: 12 months
    Secondary outcomes 3 edited
    What changed in the outcomes
    • EditedChange in conventional office blood pressure (BP)Time frame: 12 months
    • EditedHome blood pressure (BP) readingsTime frame: 12 months
    • EditedChange in standardized office diastolic blood pressure (BP)Time frame: 12 months
    + 5 other changes: identifiers, verification date, contact details, site details and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05546099
Responsible party
Sponsor
First posted
Sep 19, 2022
Start date
Dec 15, 2022
Primary completion
Dec 15, 2026 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
Oct 23, 2026

Study contacts

Diana Jalal, MD
principal investigator · Iowa City VA Health Care System, Iowa City, IA

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion